"Azepines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Seven membered heterocyclic rings containing a NITROGEN atom.
| Descriptor ID |
D001381
|
| MeSH Number(s) |
D03.383.066
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azepines".
Below are MeSH descriptors whose meaning is more specific than "Azepines".
This graph shows the total number of publications written about "Azepines" by people in this website by year, and whether "Azepines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azepines" by people in Profiles.
-
Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma. Cells. 2024 08 28; 13(17).
-
BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways. Cell Oncol (Dordr). 2020 Dec; 43(6):1049-1066.
-
Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors. Am J Clin Oncol. 2019 05; 42(5):413-420.
-
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51.
-
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149.
-
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017 Apr; 23(4):493-500.
-
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80.
-
Characterization of CpG sites that escape methylation on the inactive human X-chromosome. Epigenetics. 2015; 10(9):810-8.
-
Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma. Surgery. 2015 Sep; 158(3):819-26.
-
MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014 May 12; 25(5):652-65.